Pediatric Drugs

, Volume 12, Issue 6, pp 391–403

Strategies to Prevent Cellular Rejection in Pediatric Heart Transplant Recipients

Review Article

Abstract

Despite more than 40 years’ experience in pediatric heart transplantation, cellular rejection remains a significant cause of morbidity and mortality. In this review, strategies and agents to prevent acute cellular rejection are discussed.

Strategies to prevent rejection are divided into two phases — induction and maintenance therapies. Currently, the most commonly used induction agents are polyclonal antibodies (rabbit or equine antithymocyte globulin) and interleukin-2 receptor antibodies (daclizumab or basiliximab). Induction therapies have reduced early rejection, are renal sparing, and can reduce corticosteroid exposure, but have not yet been shown to have a longer term survival benefit. Multiple maintenance immunosuppressants are available. Nearly all regimens include a calcineurin inhibitor (either ciclosporin [cyclosporine] or tacrolimus). Most combinations in pediatric heart transplantation include an antiproliferative agent (azathioprine, mycophenolate mofetil or, less commonly, sirolimus). Everolimus has seen increasing use in adult heart transplant patients in Europe but, to date, its use is rare in pediatric heart transplantation. The use of corticosteroids as a third agent is still common, but strategies to avoid or minimize their use are increasing.

The ‘best’ combination of therapies varies between studies. By gaining a better understanding of individuals’ genetic and environmental risk factors, we may in the future be able to better predict the course of cardiac allografts and enhance our ability to tailor immunosuppression to individual patient variables with the ultimate goal of inducing a state of immune tolerance.

References

  1. 1.
    Kantrowitz A, Haller JD, Joos H, et al. Transplantation of the heart in an infant and an adult. Am J Cardiol 1968; 22: 782–90PubMedCrossRefGoogle Scholar
  2. 2.
    Boucek MM, Aurora P, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart and lung transplantation report — 2007. J Heart Lung Transplant 2007; 26: 796–807PubMedCrossRefGoogle Scholar
  3. 3.
    Kirk R, Edwards LB, Aurora P, et al. Registry of the International Society for Heart and Lung Transplantation: eleventh official pediatric heart transplantation report — 2008. J Heart Lung Transplant 2008; 27: 970–7PubMedCrossRefGoogle Scholar
  4. 4.
    Kirk R, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric heart transplantation report — 2010. J Heart Lung Transplant 2010; 29:1119–28PubMedCrossRefGoogle Scholar
  5. 5.
    Tjang YS, Stenlund H, Tenderich G, et al. Risk factor analysis in pediatric heart transplantation. J Heart Lung Transplant 2008; 27: 408–15PubMedCrossRefGoogle Scholar
  6. 6.
    Webber SA. The current state of, and future prospects for, cardiac transplantation in children. Cardiol Young 2003; 13: 64–83PubMedCrossRefGoogle Scholar
  7. 7.
    Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part I. Cardiac rejection and immunosuppressive drugs. Circulation 2004; 100: 3734–40CrossRefGoogle Scholar
  8. 8.
    Boucek RJ, Naftel D, Boucek MM, et al. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. J Heart Lung Transplant 1999; 18:460–9PubMedCrossRefGoogle Scholar
  9. 9.
    Parisi F, Danesi H, Squitieri C, et al. Thymoglobuline use in pediatric heart transplantation. J Heart Lung Transplant 2003; 22: 591–3PubMedCrossRefGoogle Scholar
  10. 10.
    DiFilippo S, Boissonnat P, Sassolas F, et al. Rabbit antithymocyte globulin as induction immunotherapy in pediatric heart transplantation. Transplantation 2003; 75: 354–8CrossRefGoogle Scholar
  11. 11.
    Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric heart and adult transplantation: comparison between OKT3 and daclizumab. Transplantation 2005; 80: 477–81PubMedCrossRefGoogle Scholar
  12. 12.
    Das B, Shoemaker L, Recto M, et al. Alemtuzumab (Campath-1H) induction in a pediatric heart transplant: successful outcome and rationale for its use. J Heart Lung Transplant 2008; 27: 242–4PubMedCrossRefGoogle Scholar
  13. 13.
    Shaddy RA, Bullock EA, Morwessel NJ, et al. Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart transplantation. J Heart Lung Transplant 1993; 12: 434–9PubMedGoogle Scholar
  14. 14.
    Pollock-BarZiv SM, Allain-Rooney T, Manlhiot C, et al. Continuous infusion of thymoglobulin for induction therapy in pediatric heart transplant recipients; experience and outcomes with a novel strategy for administration. Pediatr Transplantation 2009; 13: 585–9CrossRefGoogle Scholar
  15. 15.
    Moller CH, Gustafsson F, Gluud C, et al. Interleukin-2 receptor antagonists as induction therapy after heart transplant: systematic review with meta-analysis of randomized trials. J Heart Lung Transplant 2008; 27: 835–42PubMedCrossRefGoogle Scholar
  16. 16.
    Zuckerman AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int 2009; 22: 78–89CrossRefGoogle Scholar
  17. 17.
    Rosenberg PB, Vriesendorp AE, Drazner MH, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. J Heart Lung Transplant 2005; 24: 1327–31PubMedCrossRefGoogle Scholar
  18. 18.
    Cantarovich M, Giannetti N, Barkun J, et al. Anti-thymocyte globulin induction allows a prolonged delay in the initiation of cyclosporine in heart transplant patients with postoperative renal dysfunction. Transplantation 2004; 78: 779–81PubMedCrossRefGoogle Scholar
  19. 19.
    Delgado DH, Miriuka SG, Cusimano RJ, et al. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction. J Heart Lung Transplant 2005; 24: 166–9PubMedCrossRefGoogle Scholar
  20. 20.
    Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Chapter 59. In: Brunton LL, Lazo JS, Parker KL. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006: 1587–612Google Scholar
  21. 21.
    Berki T, Tavakoli A, Nagy KK, et al. Alterations of glucocorticoid receptor expression during glucocorticoid hormone therapy in renal transplant patients. Transpl Int 2002; 15: 132–8PubMedCrossRefGoogle Scholar
  22. 22.
    Koshiba T, Van Damme B, Ji P, et al. Addition of steroids blocks the tolerogenic potential of donor-specific blood transfusion. Transplant Proc 2002; 33: 375–6CrossRefGoogle Scholar
  23. 23.
    Wang C, Sun J, Sheil AG, et al. A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts. Transplantation 2001; 72: 44–51PubMedCrossRefGoogle Scholar
  24. 24.
    Leonard H, Hornung T, Parry G, et al. Pediatric cardiac transplant: results using a steroid free maintenance program. Pediatr Transplant 2003; 7: 59–63PubMedCrossRefGoogle Scholar
  25. 25.
    Canter CE, Moorhead S, Saffitz JE, et al. Steroid withdrawal in the pediatric heart transplant recipient initially treated with triple immunosuppression. J Heart Lung Transplant 1994; 13: 74–80PubMedGoogle Scholar
  26. 26.
    Brennan DC, Flavin K, Lowell JA, et al. A randomized, double blinded comparison of thymoglobulin versus ATGAM for induction immunosuppression therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011–8PubMedCrossRefGoogle Scholar
  27. 27.
    Reddy SC, Laughlin K, Webber SA. Immunosuppression on pediatric heart transplantation: 2003 and beyond. Curr Treat Options Cardiovasc Med 2003; 5: 412–28CrossRefGoogle Scholar
  28. 28.
    Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med 1989; 320: 1420–1PubMedCrossRefGoogle Scholar
  29. 29.
    Krensky AM, Vincenti F, Bennett WM. Immunosuppressants, tolerogens, and immunostimulants. Chapter 52. In: Brunton LL, Lazo JS, Parker KL. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006: 1405–31Google Scholar
  30. 30.
    Ford KA, Cale CM, Rees PG, et al. Initial data on basiliximab in critically ill children undergoing heart transplantation. J Heart Lung Transplant 2005; 24: 1284–8PubMedCrossRefGoogle Scholar
  31. 31.
    Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342: 613–9PubMedCrossRefGoogle Scholar
  32. 32.
    Pollock-BarZiv SM, Dipchand AI, McCrindle BW, et al. Randomized clinical trial of tacrolimus- vs cyclosporine-based immunosuppression in pediatric heart transplantation: preliminary results at 15-month follow-up. J Heart Lung Transplant 2005; 24: 190–4PubMedCrossRefGoogle Scholar
  33. 33.
    Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25: 434–9PubMedCrossRefGoogle Scholar
  34. 34.
    Ye F, Ying-Bin X, Yu-Guo W, et al. Tacrolimus versus cyclosporine micro-emulsion for heart transplant recipients: a meta-analysis. J Heart Lung Transplant 2009; 28: 58–66PubMedCrossRefGoogle Scholar
  35. 35.
    Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part II. Immunosuppessive drugs. Circulation 2004; 110: 3858–65PubMedCrossRefGoogle Scholar
  36. 36.
    Law YM, Yim R, Agatisa P, et al. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens. J Heart Lung Transplant 2006; 25: 276–82PubMedCrossRefGoogle Scholar
  37. 37.
    Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336–45PubMedCrossRefGoogle Scholar
  38. 38.
    Eisen HJ, Kobasigawa J, Keogh A, et al. Three-year results of a randomized, double blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517–25PubMedCrossRefGoogle Scholar
  39. 39.
    Hosenpud JD, Bennett LE. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the joint UNOS/ISHLT thoracic registry. Transplantation 2001; 27: 1662–5CrossRefGoogle Scholar
  40. 40.
    Kobashigawa J, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005; 80(2 Suppl.): S235–43PubMedCrossRefGoogle Scholar
  41. 41.
    Boucek MM, Pietra B, Sondheimer H, et al. Anti-T-cell-antibody prophylaxis in children: success with a novel combination strategy of mycophenolate mofetil and antithymocyte serum. Transplant Proc 1997; 29 Suppl.: S16–20CrossRefGoogle Scholar
  42. 42.
    Dipchand AI, Benson L, McCrindle BW, et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001; 5: 112–8PubMedCrossRefGoogle Scholar
  43. 43.
    Groetzner J, Reichert B, Roemer U, et al. Cardiac transplantation in pediatric patients: fifteen year experience of a single center. Ann Thorac Surg 2005; 53Suppl. 2: S149–54Google Scholar
  44. 44.
    Boyer O, Le Bidois J, Dechaux M, et al. Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. Transplantation 2005; 79: 1405–10PubMedCrossRefGoogle Scholar
  45. 45.
    Gajarski RJ, Crowley DC, Zamberlan MC, et al. Lack of correlation between MMF dose and MPA level in pediatric and young adult cardiac transplant patients: does the MPA level matter? Am J Transplant 2004; 4: 1495–00PubMedCrossRefGoogle Scholar
  46. 46.
    Dipchand AI, Pietra B, McCrindle BW, et al. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil. Pediatr Transplantation 2001; 20: 1035–43Google Scholar
  47. 47.
    Shaw LM, Holt DW, Oellrich M, et al. Current issues in therapeutic drug monitoring for mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23: 305–15PubMedCrossRefGoogle Scholar
  48. 48.
    Lobach NE, Pollock-BarZiv SM, West LJ, et al. Sirolimus immunosuppression in pediatric heart transplant recipients: a single center study. J Heart Lung Transplant 2005; 24: 184–9PubMedCrossRefGoogle Scholar
  49. 49.
    Balfour IC, Srun SW, Wood EG, et al. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplant patients. J Heart Lung Transplant 2006; 25: 518–22PubMedCrossRefGoogle Scholar
  50. 50.
    Zuckerman A, Manito N, Epailly E, et al. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation. J Heart Lung Transplant 2008; 27: 141–9CrossRefGoogle Scholar
  51. 51.
    Eisen HJ, Tuzcu EM, Dorent R, et al., and the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847–58PubMedCrossRefGoogle Scholar
  52. 52.
    Vigano M, Tuzcu M, Benza R, et al., and the RAD B253 Study Group. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis. J Heart Lung Transplant 2007; 26: 584–92PubMedCrossRefGoogle Scholar
  53. 53.
    Ettenger R, Hoyer P-F, Grimm P, et al., and the Everolimus Pediatric Study Group. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three years. Pediatr Transplantation 2008; 12: 456–63CrossRefGoogle Scholar
  54. 54.
    Pape L, Ahlensteil AT, Ehrich JHH, et al. Reversal of loss of glomerular filtration rate in children with transplant nephropathy after switch to everolimus and low-dose cyclosporine A. Pediatr Transplantation 2007; 11: 291–5CrossRefGoogle Scholar
  55. 55.
    Kusuki S, Hashii Y, Fukushima N, et al. Pediatric post-transplant diffuse large B cell lymphoma after cardiac transplantation. Int J Hematol 2009; 89:209–13PubMedCrossRefGoogle Scholar
  56. 56.
    Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A 2000; 97: 4284–90CrossRefGoogle Scholar
  57. 57.
    Chapman TM, Perry CM. Everolimus. Drugs 2004; 64: 861–72PubMedCrossRefGoogle Scholar
  58. 58.
    Moro JA, Almenar L, Martinez-Dolz L, et al. Tolerance profile of the proliferation inhibitors everolimus and sirolimus in heart transplantation. Transplant Proc 2008; 40: 3034–6PubMedCrossRefGoogle Scholar
  59. 59.
    Meiser B, Kaczmarek I, Mueller M, et al. Low-dose tacrolimus/sirolimus and steroid withdrawal in heart recipients is highly efficacious. J Heart Lung Transplant 2007; 26: 598–03PubMedCrossRefGoogle Scholar
  60. 60.
    McAllister WA, Thompson PJ, Al-Habet SM, et al. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed) 1983; 286: 923–5CrossRefGoogle Scholar
  61. 61.
    Bartoszek M, Brenner AM, Szefler SJ. Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy. Clin Pharmacol Ther 1987; 42: 424–32PubMedCrossRefGoogle Scholar
  62. 62.
    Uribe M, Casian C, Rojas S, et al. Decreased bioavailability of prednisone due to antacids in patients with chronic active liver disease and in healthy volunteers. Gastroenterology 1981; 80: 661–5PubMedGoogle Scholar
  63. 63.
    Eisen H, Ross H. Optimizing the immunosuppressive regimen in heart transplantation. J Heart Lung Transplant 2004; 23: S207–13PubMedCrossRefGoogle Scholar
  64. 64.
    Cantarovich M, Elstein E, de Varennes B, et al. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68: 1839–42PubMedCrossRefGoogle Scholar
  65. 65.
    Hmiel SP, Canter C, Shepherd R, et al. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients. Pediatr Transplantation 2007; 11: 524–9CrossRefGoogle Scholar
  66. 66.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, et al. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients. J Heart Lung Transplant 2006; 25: 619–25PubMedCrossRefGoogle Scholar
  67. 67.
    Lammers AE, Roberts P, Brown KL, et al. Acute rejection after paediatric heart transplantation: far less common and less severe. Transpl Int 2010; 23: 38–46PubMedCrossRefGoogle Scholar
  68. 68.
    Kim JJ, Dreyer WJ, Smith EO, et al. Leukocyte suppression is associated with improved clinical outcomes in children’s status after orthotopic heart transplantation. J Heart Lung Transplant 2006; 25: 195–9PubMedCrossRefGoogle Scholar
  69. 69.
    Morales DLS, Dreyer WJ, Denfield SW, et al. Over two decades of pediatric heart transplantation: how has survival changed? J Thorac Cardiovasc Surg 2007; 133: 632–9PubMedCrossRefGoogle Scholar
  70. 70.
    Chin C, Naftel CD, Singh TP, et al., and the Pediatric Heart Transplant Study Group. Risk factors for recurrent rejection in pediatric heart transplantation: a multicenter experience. J Heart Lung Transplant 2004; 23: 178–85PubMedCrossRefGoogle Scholar
  71. 71.
    Awad MR, Webber S, Boyle G, et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 2001; 20: 615–30CrossRefGoogle Scholar
  72. 72.
    Hoffman SC, Stanley EM, Cox ED, et al. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2002; 2: 560–7CrossRefGoogle Scholar
  73. 73.
    Webber SA, Naftel DC, Parker J, et al., and the Pediatric Heart Transplant Study Group. Late rejection episodes more than 1 year after pediatric heart transplantation: risk factors and outcomes. J Heart Lung Transplant 2003; 22: 869–75PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Texas Children’s HospitalBaylor College of MedicineHoustonUSA
  2. 2.Texas Children’s HospitalHoustonUSA

Personalised recommendations